CICC: Maintains Outperform Rating on GJS Biotech (02367), Lowers Target Price to HKD 56

According to the Wise Finance APP, Zhongjin released a research report stating that due to short-term pressure on cosmetics sales, it has lowered its net profit forecast for Juzi Biotech (02367) for 2025-2026 by 25%/33% to 19.1/21.4 billion yuan. The current stock price corresponds to a P/E ratio of 20/18x for 2025-2026. The rating remains outperform the industry, based on adjusted profit forecasts and the company's long-term competitive advantage stability. The target price is lowered by 20% to 56 Hong Kong dollars, corresponding to a P/E ratio of 29/25x for 2025-2026, with a 41% upside potential.